NICE Reforms, AI Scribes in Practice, Cross-Border NHS Challenges, and New Funding Fuels UK Innovation
Welcome back. This week’s had me thinking about just how quickly healthtech is evolving, and how the lines between science fiction and reality keep getting blurrier.
Let’s start with AI powering the future of healthtech, which gives a solid overview of how artificial intelligence is becoming central to healthcare innovation. From drug discovery to diagnostics, the pace is accelerating. What stood out to me was the reminder that while the tech itself is evolving, the real differentiator is in how it's applied, not just what AI can do, but how it's being embedded in actual workflows.
A perfect example of this comes from Navina’s recent $55M Series C. They’re using AI to sift through the endless noise of patient data and serve up what matters most to clinicians. It’s not replacing the doctor, it’s reducing friction, and that’s a pattern we’re seeing more often. Similarly, the Insight Partners sale of CentralReach suggests investors are starting to prioritise operational platforms that deliver real value across the continuum of care.
Still, AI isn’t magic, and that was clear in an STAT News article questioning the ROI of AI scribes. While AI assistants are supposed to save doctors time, the early results are mixed. Some clinicians say it adds time, not subtracts it, especially when double-checking transcriptions. It raises the same question we’ve asked internally: is the tech solving the right problem, or just shifting the problem around?
What’s even more interesting is how HealthTech isn’t just going smarter, it’s also going smaller and more precise. Imperial College’s new Centre for In Vitro Therapeutics is pushing innovation in drug delivery and organ-on-chip models. And over in Birmingham, researchers are literally working in the fourth dimension, developing materials that respond and evolve over time, think of medical implants that adjust themselves based on the patient’s healing. That’s not hypothetical; they’re actively prototyping it.
Juro Medicine’s $12M raise in Poland shows how telehealth is still attracting capital in Eastern Europe. Their focus on making remote consultations faster and more efficient is a reminder that the demand for accessible, affordable care isn’t slowing down, if anything, it’s expanding into markets with previously limited infrastructure.
That broader perspective ties in with this WSJ article on healthtech VC trends. The big takeaway: venture funds are chasing companies that can show real-world clinical impact, not just fancy algorithms. The hype cycle is giving way to a more pragmatic lens. We’re watching the sector mature in real time.
At the systems level, Europe is under pressure to catch up. There’s growing awareness that if European nations don’t standardise and accelerate digital health adoption, they’ll fall behind. What's missing isn’t the talent or the tech, but the political will and interoperability frameworks that make scaling possible.
And speaking of frameworks, this short guide on Retrieval-Augmented Generation (RAG) does a great job breaking down one of the newer techniques behind AI’s smarter outputs. For those of you working with structured knowledge bases, it’s worth skimming. RAG makes it possible for AI to pull from actual, up-to-date sources instead of relying on what it “remembers” a small change with big implications for accuracy and transparency.
All in all, this week felt like a snapshot of a sector coming into its own. The tech is maturing, the money is following substance, and the gaps, whether in trust, integration, or actual utility, are finally being addressed out in the open.
What I’m left asking is: are we building systems that HCPs and patients want to use, or ones they’ll just have to tolerate? Because the answer to that question will ultimately determine which innovations stick, and which quietly fade away.
You might like these recent posts as well:
Thanks for reading.
Until next time!